Transcat (NASDAQ:TRNS) Issues Earnings Results

Transcat (NASDAQ:TRNS) released its earnings results on Tuesday. The scientific and technical instruments company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.19, FiscalAI reports. Transcat had a net margin of 1.26% and a return on equity of 6.18%. The company had revenue of $97.09 million for the quarter, compared to analysts’ expectations of $92.46 million.

Here are the key takeaways from Transcat’s conference call:

• Strong second-quarter growth: Revenue increased 18% to $97.1 million, while adjusted EBITDA rose 23% and adjusted EPS grew 46% to $0.64. Service revenue grew 23%, including 16% organic growth, marking the 70th consecutive quarter of year-over-year service growth.
• Service profitability improved substantially: Service gross margin expanded 220 basis points to 34.4%, helped by operating leverage, pricing, business-mix improvements, and operational-excellence initiatives. Management expects at least 100 basis points of year-over-year service gross-margin expansion in the second half.
• Full-year service outlook was raised: Transcat increased its fiscal 2027 service organic revenue-growth forecast from high single digits to low double digits, citing broad-based demand, market-share gains, improved sales execution, and better visibility into large customer wins.
• Acquisition and rental strategies remain key growth drivers: The Southeastern Biomedical Associates acquisition expands Transcat’s reach in biomedical calibration and hospital networks, while rentals are expected to grow at a low-double-digit rate over time. Distribution margins declined year over year because of lower-margin used-equipment sales, but management expects distribution-margin improvement in the second half.
• Financial capacity supports continued expansion: Operating free cash flow rose 46% to $10.9 million in the first half, while quarter-end debt was $116.9 million, with $33.1 million available under the revolving credit facility and leverage of 2.18 times.

Transcat Trading Up 20.8%

NASDAQ:TRNS opened at $108.13 on Thursday. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 225.28 and a beta of 0.61. Transcat has a 52 week low of $50.23 and a 52 week high of $110.47. The company has a quick ratio of 2.11, a current ratio of 2.49 and a debt-to-equity ratio of 0.36. The firm has a 50 day moving average of $86.49 and a 200 day moving average of $82.05.

Insider Buying and Selling at Transcat

In related news, Director Christopher P. Gillette sold 504 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $94.23, for a total transaction of $47,491.92. Following the completion of the transaction, the director owned 200 shares of the company’s stock, valued at $18,846. This trade represents a 71.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.80% of the stock is owned by company insiders.

Trending Headlines about Transcat

Here are the key news stories impacting Transcat this week:

• Positive Sentiment: Transcat reported adjusted earnings of $0.64 per share, above analysts’ estimate of about $0.45, while revenue of $97.09 million topped expectations of $92.46 million. Earnings also increased from $0.44 per share a year earlier. Transcat Q2 earnings and revenue results
• Positive Sentiment: Management raised its fiscal 2027 service organic-growth outlook to the low double digits and expects at least 100 basis points of service gross-margin expansion in the second half. Strong service momentum and acquisitions helped drive the quarter, supporting the improved outlook. Transcat raises service growth outlook
• Positive Sentiment: Oppenheimer upgraded TRNS from “market perform” to “outperform” and set a $115 price target, adding to the positive reaction to results and guidance.
• Negative Sentiment: After a sharp rally to record levels, valuation may be a consideration for investors: the supplied stock data puts the P/E ratio above 225, leaving shares potentially sensitive to any slowdown in growth or margin progress.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TRNS. Northland Securities upgraded Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 price target for the company in a research report on Wednesday, October 21st. CJS Securities started coverage on shares of Transcat in a research note on Tuesday, October 27th. They issued an “outperform” rating and a $115.00 target price on the stock. Oppenheimer upgraded shares of Transcat from a “market perform” rating to an “outperform” rating and set a $115.00 target price for the company in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Transcat in a research note on Tuesday, August 25th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Transcat has a consensus rating of “Hold” and a consensus target price of $108.33.

About Transcat

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.